Docket No. CRD 0938



Applicants : Luis A. Davila et al.

Serial No.: 09/884,729

Art Unit: 3738

Filed

: June 19, 2001

Examiner:

K.R. Landrem

For.

: Radiopacity Intraluminal Medical Device

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Commissioner For Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on

(Name of applicant, assignee, or Registered Representative)

(Signature)

(Date of Signature)

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT

Dear Sir:

Pursuant to 37 C.F.R. §1.56 and in accordance with 37 C.F.R. §§1.97-1.98, information relating to the above-identified application is hereby disclosed. Inclusion of information in this statement is not to be construed as an admission that this information is material as that term is defined in 37 C.F.R. §1.56(b).

Applicant(s) reserve(s) the right to establish the patentability of the claimed invention over any of the information provided herewith, and/or to prove that this information may not be prior art, and/or to prove that this information may not be enabling for the teachings purportedly offered.

This statement should not be construed as a representation that a search has been made, or that information more material to the examination of the present patent application does not exist. \boxtimes In accordance with §1.97(b), since this Information Disclosure Statement is being filed either within three months of the filing date of the above-identified national application (other than a continued prosecution application under §1.53(d)), within three months of the date of entry into the national stage of the above identified application as set forth in §1.491, or before the mailing date of a first Office Action on the merits of the above-identified application, or before the mailing date of a first Office Action after the filing of a request for continued examination under §1.114, no additional fee is required.

In accordance with §1.129(a), this Information
Disclosure Statement is being filed in connection with [] the
first or second After Final Submission, therefore:
<pre>Statement in Accordance with §1.97(e)</pre>
(attached); or
☐ Please charge Deposit Account No. 10-
0750/ / the fee of $$180.00$ as set forth
in §1.17(p).
In accordance with §1.97(c), this Information
Disclosure Statement is being filed after the period set forth
in §1.97(b) above but before the mailing date of either a Final
Action under §1.113 or a Notice of Allowance under §1.311, or
an action that otherwise closes prosecution and that it is
accompanied by one of:
Statement in Accordance with §1.97(e)
(attached); or

Please charge Deposit Account No. 10-	÷
0750/ / the fee of $$180.00$ as set forth	
in §1.17(p).	
In accordance with §1.97(d), this Information	• "
Disclosure Statement is being filed after the mailing date of	
either a Final Action under §1.113 or a Notice of Allowance	
under §1.311 but before the payment of the Issue Fee.	
Applicant(s) hereby petition(s) for consideration of this	
Information Disclosure Statement. Included are: Statement in	
Accordance with §1.97(e) as set forth below and the fee of	
\$180.00 as set forth in §1.17(p).	
igties Copies of each of the references listed on the	
attached Form PTO-1449 are enclosed herewith.	
Copies of references listed on the attached Form PTO-	
1449 are enclosed herewith EXCEPT THAT:	
In view of the voluminous nature of references	
[list as appropriate], and the likelihood that	
these references are available to the Examiner,	
copies are not enclosed herewith.	
<pre>If any of the foregoing publications are not</pre>	•
available to the Examiner, Applicant will	
endeavor to supply copies at the Examiner's	•
request.	
Copies of only foreign patent documents and non-	
patent literature are enclosed in accordance with 37 CFR 1.98	
(a)(2). (The U.S. patents and each U.S. patent application	
publication listed on the attached Form PTO-1449 are not	
enclosed because this U.S. patent application was filed after	
June 30, 2003 or this international application has entered the	·
- 3 -	

national stage under 35 USC §371 after June 30, 2003 (see USPTO waiver of requirement under 37 CFR 1.98 (a)(2)(i). There are no listed references which are not in the English language. The relevance of those listed references which are not in the English language is as follows: Attached are copies of search report(s) from corresponding patent application(s), which are listed on the attached Submission Under MPEP 609 D. Attached are the following non-published pending patent applications which may be deemed relevant, which are listed on the attached Submission Under MPEP 609 D. Please charge any deficiency or credit any overpayment to Deposit Account No. 10-0750/CRD0938/CJE. This form is submitted in triplicate. Respectfully submitted, Carl J. Evens Reg. No. 33,874 Attorney for Applicants Johnson & Johnson One Johnson & Johnson Plaza New Brunswick, NJ 08933-7003 (732) 524-2518 DATED:

r the Part Marin Badagan and col 1995, no persons are required to respond to a

PTO/SB/08A (08-00)
Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

for form 1449A/PT/T

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)
Sheet 1 of 1

_	a collection of information diffess it displays a valid Olyb control number.					
	Application Number	09/884,729				
ļ	Filing Date	June 19, 2001				
	First Named Inventor	Luis A. Davila				
Ì	Group Art Unit	3738				
Ì	Examiner Name	Landrem				
	Attorney Docket Number	CRD-0938				

U.S. PATENT DOCUMENTS

		U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document mm-dd-yyyy	Pages, Columns, Lines, where relevant passages or relevant figures appear
Examiner Initials	Cite No. ¹	. Kind Code ² Number (if known)				
		5,824,042	Α	Lombardi et al.	10-20-1998	
		6,203,569	¹ B1	Wijay	03-20-2001	
		6,231,598	B1 .	Berry et al.	05-15-2001	
		6,203,569	B1	Frantzen	09-25-2001	
		6,315,790	B1	Gerberding et al.	11-13-2001	
,						
					·	

FOREIGN PATENT DOCUMENTS

		Foreign Patent Document			Name of Datastas or	Date of Publication of Cited Document	Pages, Columns, Lines, where relevant	
Examiner Initials	Cite No. ¹	Office ³ Number ⁴ KindCode ⁵		ndCode⁵	Name of Patentee or Applicant of Cited Document	mm-dd-yyyy	passages or relevant figures appear	Т6
		EP	0894481	A2	Schneider (USA) Inc.	02-03-1999		
		EP	0895760	A1 .	Sorin Biomedica Cardio S.p.A.	02-10-1999		
		EP	0945107	A2	Arterial Vascular Engineering Inc.	09-29-1999		•
		wo	95/03010	A1	Cook Incorporated	02-02-1995		
		wo	97/33534	A1	Medtronic Inc.	09-18-1997		
		wo	99/30643	A1	Surface Genesis, Inc.	06-24-1999		
		wo	02/15820	A2	Giomed GMBH & Co. Medizintechnik	02-28-2002		

	•		
Examiner		Date	
Signature	·	Considered	

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS, SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450

¹ Unique citation designation number. 2 See attached Kinds of U.S. Patent Documents. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. 6 Applicant is to place a check mark here if English language Translation is attached.